Pfizer to Acquire ADC Cancer Specialist Seagen for US$43 B

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)

Published: 15 Mar-2023

DOI: 10.3833/pdr.v2023.i3.2770     ISSN: 1756-7874

Section: Mergers & Acquisitions



In the biggest M&A deal since 2019, Pfizer has agreed to acquire Seagen for US$299 in cash per Seagen share, representing a total enterprise value of US$43 B and a 33% premium to Seagen’s closing price the day prior to the announcement...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details